PE Tech Report


Like this article?

Sign up to our free newsletter

finnCap adds two to Life Sciences team

finnCap Group has appointed Nigel Birks and Dr Susie Jana as Directors in its Life Sciences team. 

Birks joins as Equity Capital Markets Director with a remit to enhance the firm’s institutional and corporate relationships while Jana is joining the research team to expand the growth trajectory of the franchise following its strong performance over the past year.
The appointments will strengthen finnCap’s Life Sciences franchise and build upon its leading sector expertise and capital markets capabilities. Against the backdrop of the pandemic, Life Sciences is a market ripe for disruption and rapid expansion, in line with finnCap’s mission to create growth, change and innovation for the businesses of tomorrow. The team’s strong sector knowledge and full-service offering enables it to identify and provide the right solution to meet its clients’ growth needs, whether that be fundraising, M&A, debt or a potential IPO. finnCap currently has 16 life sciences clients and has been the leading adviser in the public life sciences sector for five years.
The team has a strong track record of capital raising within the sector in both public and private markets, raising GBP300 million since March 2020. Most recently, finnCap advised on the GBP80 million fundraise for Synairgen plc, the GBP29 million fundraise for Shield Therapeutics plc and on the GBP25 million IPO fundraise for Poolbeg Pharma plc.
Birks has had a 30-year career in life sciences. He has led the research team at Dresden Kleinwort, covering EU and US pharma, medtech and biotech companies and executed multiple European and UK capital raises. Following his MBA in management, Birks worked for Eli Lilly and subsequently ZS Associates, a US life science consultancy. Most recently he advised UK, European and Australian life science companies on capital market transactions, managing institutional investor relationships and leading a team of four specialist sales.
SuJanasie, a qualified medical doctor, has over 20 years’ experience in equity research, including five years as a buy-side analyst in healthcare, luxury and consumers goods and over 15 years as a sell-side analyst covering large, mid-cap pharmaceutical and biotechnology stocks. Having studied at UCL and worked in the NHS as a hospital doctor for a number of years, Jana has an exceptional background in healthcare. 
Sam Smith, Chief Executive of finnCap Group, says: “Nigel’s extensive investment banking track record and Susie’s medical background, coupled with their wealth of experience in the life sciences sector, will greatly enhance the team’s capital markets capabilities, and enable finnCap to originate and execute opportunities for our diverse range of clients in the sector.”
Birks says: “It’s an exciting time to be joining finnCap with so much corporate activity in the pipeline, particularly in the life sciences sector. I’m hugely enthused about the ambition for the business and look forward to working with this successful and dynamic team.”
Jana says: “I am delighted to be joining finnCap Group and working in its leading Life Sciences team. It’s fantastic to be working with a highly knowledgeable and experienced team that has built the company to a position of strength – completing several impressive transactions over the past year and building an exciting upcoming pipeline. I look forward to sharing my knowledge and expanding the team’s existing capabilities and sector expertise.”

Like this article? Sign up to our free newsletter